Neurogene Inc. (NGNE) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth No data.
25/51
2.5 / 5 stars
All 51 Win/Lose results and 69 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 4 wins, 3 losses, 5 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinNGNE / S&P 56.00% / 15.20% |
No dataNGNE / S&P / 15.00% |
LoseNGNE / S&P 16.94% / 50.40% |
| 2026-Q11/2 |
WinNGNE / S&P -2.14% / -4.33% |
No dataNGNE / S&P / 11.30% |
LoseNGNE / S&P 4.83% / 27.70% |
| 2025-Q41/2 |
WinNGNE / S&P 18.87% / 2.65% |
No dataNGNE / S&P / 9.00% |
LoseNGNE / S&P -0.47% / 13.40% |
| 2025-Q31/1 |
WinNGNE / S&P 15.92% / 8.12% |
No dataNGNE / S&P / 4.61% |
No dataNGNE / S&P / 13.45% |
| 2025-Q21/1 |
WinNGNE / S&P 27.67% / 10.94% |
No dataNGNE / S&P / 4.83% |
No dataNGNE / S&P / 10.63% |
| 2025-Q10/1 |
LoseNGNE / S&P -48.78% / -4.27% |
No dataNGNE / S&P / 4.98% |
No dataNGNE / S&P / 10.57% |
| 2024-Q40/1 |
LoseNGNE / S&P -45.52% / 2.41% |
No dataNGNE / S&P / 5.25% |
No dataNGNE / S&P / 6.15% |
| 2024-Q31/1 |
WinNGNE / S&P 15.31% / 5.89% |
No dataNGNE / S&P / 5.89% |
No dataNGNE / S&P / 6.11% |
| 2024-Q20/1 |
LoseNGNE / S&P -28.51% / 4.28% |
No dataNGNE / S&P / 5.38% |
No dataNGNE / S&P / 5.12% |
| 2024-Q11/1 |
WinNGNE / S&P 162.64% / 10.56% |
No dataNGNE / S&P / 5.71% |
No dataNGNE / S&P / 5.59% |
| 2023-Q41/1 |
WinNGNE / S&P 22.66% / 11.69% |
No dataNGNE / S&P / 6.81% |
No dataNGNE / S&P / 7.78% |
| 2023-Q31/2 |
LoseNGNE / S&P -4.82% / -3.27% |
No dataNGNE / S&P / 7.52% |
WinNGNE / S&P 2718.91% / -5.03% |
| 2023-Q22/2 |
WinNGNE / S&P 18.57% / 8.74% |
No dataNGNE / S&P / 9.50% |
WinNGNE / S&P 2167.57% / -8.57% |
| 2023-Q11/2 |
WinNGNE / S&P 37.52% / 7.50% |
No dataNGNE / S&P / 10.77% |
LoseNGNE / S&P -211.82% / -15.69% |
| 2022-Q40/2 |
LoseNGNE / S&P -20.47% / 7.56% |
No dataNGNE / S&P / 11.88% |
LoseNGNE / S&P -211.01% / -17.99% |
| 2022-Q31/2 |
LoseNGNE / S&P -37.86% / -4.88% |
No dataNGNE / S&P / 13.47% |
WinNGNE / S&P 91.43% / -1.41% |
| 2022-Q21/2 |
LoseNGNE / S&P -45.21% / -16.10% |
No dataNGNE / S&P / 13.71% |
WinNGNE / S&P 37.04% / 11.04% |
| 2022-Q11/2 |
LoseNGNE / S&P -61.00% / -4.60% |
No dataNGNE / S&P / 15.97% |
WinNGNE / S&P 48.65% / 42.23% |
| 2021-Q40/2 |
LoseNGNE / S&P -33.33% / 11.03% |
No dataNGNE / S&P / 15.00% |
LoseNGNE / S&P 67.69% / 96.40% |
| 2021-Q30/1 |
LoseNGNE / S&P -21.67% / 0.58% |
No dataNGNE / S&P / 10.77% |
No dataNGNE / S&P / 69.42% |
| 2021-Q20/1 |
LoseNGNE / S&P -25.02% / 8.55% |
No dataNGNE / S&P / 6.58% |
No dataNGNE / S&P / 51.81% |
| 2021-Q10/1 |
LoseNGNE / S&P -12.70% / 6.17% |
No dataNGNE / S&P / -1.06% |
No dataNGNE / S&P / 7.39% |
| 2020-Q41/1 |
WinNGNE / S&P 17.50% / 12.15% |
No dataNGNE / S&P / -3.72% |
No dataNGNE / S&P / -33.42% |
| 2020-Q30/1 |
LoseNGNE / S&P -27.71% / 8.93% |
No dataNGNE / S&P / -2.04% |
No dataNGNE / S&P / -27.10% |
| 2020-Q21/1 |
WinNGNE / S&P 45.87% / 20.54% |
No dataNGNE / S&P / -0.46% |
No dataNGNE / S&P / -27.11% |
| 2020-Q11/1 |
WinNGNE / S&P -7.63% / -19.60% |
No dataNGNE / S&P / 3.47% |
No dataNGNE / S&P / -14.75% |
| 2019-Q41/1 |
WinNGNE / S&P 332.28% / 9.07% |
No dataNGNE / S&P / 5.36% |
No dataNGNE / S&P / 2.99% |
| 2019-Q31/1 |
WinNGNE / S&P 20.76% / 1.70% |
No dataNGNE / S&P / 5.02% |
No dataNGNE / S&P / 0.21% |
| 2019-Q20/1 |
LoseNGNE / S&P -12.43% / 4.30% |
No dataNGNE / S&P / 6.64% |
No dataNGNE / S&P / 8.65% |
| 2019-Q11/1 |
WinNGNE / S&P 24.77% / 13.65% |
No dataNGNE / S&P / 8.12% |
No dataNGNE / S&P / 14.29% |
| 2018-Q40/1 |
LoseNGNE / S&P -26.28% / -13.52% |
No dataNGNE / S&P / 9.05% |
No dataNGNE / S&P / 18.23% |
| 2018-Q31/1 |
WinNGNE / S&P 10.57% / 7.71% |
No dataNGNE / S&P / 10.21% |
No dataNGNE / S&P / 19.06% |
| 2018-Q20/1 |
LoseNGNE / S&P -81.18% / 3.43% |
No dataNGNE / S&P / 9.03% |
No dataNGNE / S&P / 14.46% |
| 2018-Q11/1 |
WinNGNE / S&P 19.73% / -0.76% |
No dataNGNE / S&P / 7.68% |
No dataNGNE / S&P / 12.46% |
| 2017-Q40/1 |
LoseNGNE / S&P -17.12% / 6.64% |
No dataNGNE / S&P / 7.03% |
No dataNGNE / S&P / 13.82% |
| 2017-Q30/1 |
LoseNGNE / S&P 0.85% / 4.48% |
No dataNGNE / S&P / 5.68% |
No dataNGNE / S&P / 17.57% |
| 2017-Q20/1 |
LoseNGNE / S&P -15.70% / 3.09% |
No dataNGNE / S&P / 4.83% |
No dataNGNE / S&P / 17.74% |
| 2017-Q10/1 |
LoseNGNE / S&P 1.09% / 6.07% |
No dataNGNE / S&P / 3.67% |
No dataNGNE / S&P / 13.32% |
| 2016-Q41/1 |
WinNGNE / S&P 23.58% / 3.82% |
No dataNGNE / S&P / 2.09% |
No dataNGNE / S&P / 7.05% |
| 2016-Q31/1 |
WinNGNE / S&P 101.81% / 3.85% |
No dataNGNE / S&P / 0.20% |
No dataNGNE / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NGNE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 104.87% | 20.78% |
| Annualized return | 104.87% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NGNE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -76.51% | 83.14% |
| Annualized return | -25.15% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NGNE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -84.53% | 319.30% |
| Annualized return | -17.03% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |